Brain Cancer | Specialty

Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune Suppression

November 21st 2015

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

November 21st 2015

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

November 20th 2015

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

November 20th 2015

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Second-Line Optune Improves Survival in GBM

November 20th 2015

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.

Dr. Reardon on Updated Data From the Phase II ReACT Trial

November 20th 2015

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE Management

November 20th 2015

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

October 29th 2015

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Three FDA Approvals and Two Priority Reviews

October 9th 2015

FDA Expands Optune's Glioblastoma Multiforme Indication

October 5th 2015

The FDA has approved Optune in combination with adjuvant temozolomide as a treatment for patients with newly diagnosed glioblastoma multiforme following surgery, chemotherapy, and radiation therapy.

Dr. Piccioni on Tumor Profiles of Brain Metastases

September 2nd 2015

David Piccioni, MD, PhD, assistant professor, Neuroscience and Neuro-Oncology, UC San Diego Health, discusses tumor profiling of brain metastases of patients with non-small cell lung cancer, breast cancer, and melanoma.

Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future Perspectives

August 9th 2015

Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.

Lenalidomide Highly Effective in Early Phase CNS Lymphoma Study

June 20th 2015

Lenalidomide in combination with rituximab and as maintenance monotherapy is highly active in patients with relapsed/refractory central nervous system non-Hodgkin lymphoma.

Dr. Michalski on Minimizing Long-Term Consequences of Radiation

May 5th 2015

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center explains the importance of minimizing the long-term consequences of radiation.

Dr. Daniel Brat on Characterizing Diffuse Lower Grade Gliomas

April 27th 2015

Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.

Liposomal Encapsulation of Radiotherapeutics Holds Promise in Treating Glioblastoma

April 8th 2015

Andrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.

Dr. Battiste on Biomarkers in Glioblastoma

March 19th 2015

James Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).

FDA Approvals, Breakthrough Designations, Priority Reviews, and More

February 27th 2015

FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma

February 23rd 2015

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014